Lanean...

Early Failure of Frontline Rituximab-containing Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma does not Predict Futility of Autologous Hematopoietic Cell Transplantation

The poor prognosis of diffuse large B-cell lymphoma (DLBCL) patients relapsing within 1-year of initial diagnosis after first-line rituximab-based chemoimmunotherapy has created controversy about the role of autologous transplantation (auto-HCT) in this setting. We compared auto-HCT outcomes of chem...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hamadani, Mehdi, Hari, Parameswaran N., Zhang, Ying, Carreras, Jeanette, Akpek, Görgün, Aljurf, Mahmoud D., Ayala, Ernesto, Bachanova, Veronika, Chen, Andy I., Chen, Yi-Bin, Costa, Luciano J., Fenske, Timothy S., Freytes, César O., Ganguly, Siddhartha, Hertzberg, Mark S., Holmberg, Leona A., Inwards, David J., Kamble, Rammurti T., Kanfer, Edward J., Lazarus, Hillard M., Marks, David I., Nishihori, Taiga, Olsson, Richard, Reddy, Nishitha M., Rizzieri, David A., Savani, Bipin N., Solh, Melhem, Vose, Julie M., Wirk, Baldeep, Maloney, David G., Smith, Sonali M., Montoto, Silvia, Saber, Wael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4194275/
https://ncbi.nlm.nih.gov/pubmed/25008330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.06.036
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!